Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies
Related Experiment Video
Updated: Aug 3, 2026

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
Published on: August 29, 2017
1Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK. G.Giovannoni@ion.ucl.ac.uk
Abstract:
Up to 35% of people with multiple sclerosis (MS) treated with interferon-beta (IFNbeta) develop neutralizing anti-IFNbeta antibodies within 2 years of starting therapy. These antibodies reduce or abolish the biologic effects and clinical efficacy of IFNbeta. The overall efficacy of IFNbeta and hence the cost-effectiveness of this treatment would be substantially improved if the development of neutralizing antibodies (NAbs) could be prevented or reversed. Strategies used to prevent or reverse the development of NAbs with other biologic compounds, including improvements in the manufacturing process, immunosuppression, induction of tolerance, and deimmunization, will be reviewed.
More Related Videos
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Related Concept Videos
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors